Protein N-terminal acetyltransferases in cancer

Oncogene

Volumn 32, Issue 3, 2013, Pages 269-276

  Kalvik, T V ^a   Arnesen, T ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

N terminal acetylation; Naa10p; NAT; oncoprotein; tumor suppressor

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA METHYLTRANSFERASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MYOSIN LIGHT CHAIN KINASE; ONCOPROTEIN; P21 ACTIVATED KINASE INTERACTING EXCHANGE FACTOR; PEPTIDE ALPHA N ACETYLTRANSFERASE; PROTEIN; PROTEIN CDC42; RAC1 PROTEIN; TUBERIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ACETYLATION; AMINO TERMINAL SEQUENCE; APOPTOSIS; AUTOPHAGY; CANCER CELL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; HUMAN; HYPOXIA; METABOLISM; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; N-TERMINAL ACETYLTRANSFERASES; NEOPLASMS;

EID: 84872613178     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.82     Document Type: Review

References (88)

1. Arnesen T, Van Damme P, Polevoda B, Helsens K, Evjenth R, Colaert N et al. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc Natl Acad Sci USA 2009; 106: 8157-8162.
2. Van Damme P, Hole K, Pimenta-Marques A, Helsens K, Vandekerckhove J, Martinho RG et al. NatF contributes to an evolutionary shift in protein N-terminal acetylation and is important for normal chromosome segregation. PLoS Genet 2011; 7: e1002169.
3. Brown JL, Roberts WK. Evidence that approximately eighty per cent of the soluble proteins from Ehrlich ascites cells are Nalpha-acetylated. J Biol Chem 1976; 251: 1009-1014.
4. Polevoda B, Sherman F. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J Mol Biol 2003; 325: 595-622.
5. Hershko A, Heller H, Eytan E, Kaklij G, Rose IA. Role of the alpha-amino group of protein in ubiquitin-mediated protein breakdown. Proc Natl Acad Sci USA 1984; 81: 7021-7025.
6. Hwang CS, Shemorry A, Varshavsky A. N-terminal acetylation of cellular proteins creates specific degradation signals. Science 2010; 327: 973-977.
7. Varshavsky A. The N-end rule pathway and regulation by proteolysis. Protein Sci 2011; 20: 1298-1345.
8. Scott DC, Monda JK, Bennett EJ, Harper JW, Schulman BA. N-terminal acetylation acts as an avidity enhancer within an interconnected multiprotein complex. Science 2011; 334: 674-678.
9. Polevoda B, Cardillo TS, Doyle TC, Bedi GS, Sherman F. Nat3p and Mdm20p are required for function of yeast NatB Nalpha-terminal acetyltransferase and of actin and tropomyosin. J Biol Chem 2003; 278: 30686-30697.
10. Caesar R, Blomberg A. The stress-induced Tfs1p requires NatB-mediated acetylation to inhibit carboxypeptidase Y and to regulate the protein kinase A pathway. J Biol Chem 2004; 279: 38532-38543.
11. Coulton AT, East DA, Galinska-Rakoczy A, Lehman W, Mulvihill DP. The recruitment of acetylated and unacetylated tropomyosin to distinct actin polymers permits the discrete regulation of specific myosins in fission yeast. J Cell Sci 2010; 123 (Part 19): 3235-3243.
12. Hofmann I, Munro S. An N-terminally acetylated Arf-like GTPase is localised to lysosomes and affects their motility. J Cell Sci 2006; 119 (Part 8): 1494-1503.
13. Setty SR, Strochlic TI, Tong AH, Boone C, Burd CG. Golgi targeting of ARF-like GTPase Arl3p requires its Nalpha-acetylation and the integral membrane protein Sys1p. Nat Cell Biol 2004; 6: 414-419.
14. Behnia R, Panic B, Whyte JR, Munro S. Targeting of the Arf-like GTPase Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p. Nat Cell Biol 2004; 6: 405-413.
15. Starheim KK, Gromyko D, Evjenth R, Ryningen A, Varhaug JE, Lillehaug JR et al. Knockdown of human N alpha-terminal acetyltransferase complex C leads to p53-dependent apoptosis and aberrant human Arl8b localization. Mol Cell Biol 2009; 29: 3569-3581.
16. Behnia R, Barr FA, Flanagan JJ, Barlowe C, Munro S. The yeast orthologue of GRASP65 forms a complex with a coiled-coil protein that contributes to ER to Golgi traffic. J Cell Biol 2007; 176: 255-261.
17. Murthi A, Hopper AK. Genome-wide screen for inner nuclear membrane protein targeting in Saccharomyces cerevisiae: roles for N-acetylation and an integral membrane protein. Genetics 2005; 170: 1553-1560.
18. Forte GM, Pool MR, Stirling CJ. N-terminal acetylation inhibits protein targeting to the endoplasmic reticulum. PLoS Biol 2011; 9: e1001073.
19. Arnesen T. Towards a functional understanding of protein N-terminal acetylation. PLoS Biol 2011; 9: e1001074.
20. Driessen HP, de Jong WW, Tesser GI, Bloemendal H. The mechanism of N-terminal acetylation of proteins. CRC Crit Rev Biochem 1985; 18: 281-325.
21. Polevoda B, Brown S, Cardillo TS, Rigby S, Sherman F. Yeast N(alpha)-terminal acetyltransferases are associated with ribosomes. J Cell Biochem 2008; 103: 492-508.
22. Gautschi M, Just S, Mun A, Ross S, Rucknagel P, Dubaquie Y et al. The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides. Mol Cell Biol 2003; 23: 7403-7414.
23. Helsens K, Van Damme P, Degroeve S, Martens L, Arnesen T, Vandekerckhove J et al. Bioinformatics analysis of a Saccharomyces cerevisiae N-terminal proteome provides evidence of alternative translation initiation and post-translational N-terminal acetylation. J Proteome Res 2011; 10: 3578-3589.
24. Helbig AO, Rosati S, Pijnappel PW, van Breukelen B, Timmers MH, Mohammed S et al. Perturbation of the yeast N-acetyltransferase NatB induces elevation of protein phosphorylation levels. BMC Genomics 2010; 11: 685.
25. Polevoda B, Norbeck J, Takakura H, Blomberg A, Sherman F. Identification and specificities of N-terminal acetyltransferases from Saccharomyces cerevisiae. EMBO J 1999; 18: 6155-6168.
26. Polevoda B, Arnesen T, Sherman F. A synopsis of eukaryotic Nalpha-terminal acetyltransferases: nomenclature, subunits and substrates. BMC Proc 2009; 3 (Suppl 6): S2.
27. Evjenth R, Hole K, Karlsen OA, Ziegler M, Arnesen T, Lillehaug JR. Human Naa50p (Nat5/San) displays both protein N alpha-and N epsilon-acetyltransferase activity. J Biol Chem 2009; 284: 31122-31129.
28. Starheim KK, Arnesen T, Gromyko D, Ryningen A, Varhaug JE, Lillehaug JR. Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a complex important for cell-cycle progression. Biochem J 2008; 415: 325-331.
29. Arnesen T, Anderson D, Baldersheim C, Lanotte M, Varhaug JE, Lillehaug JR. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem J 2005; 386(Part 3): 433-443.
30. Hole K, Van Damme P, Dalva M, Aksnes H, Glomnes N, Varhaug JE et al. The human N-alpha-acetyltransferase 40 (hNaa40p/hNatD) is conserved from yeast and N-terminally acetylates histones H2A and H4. PLoS One 2011; 6: e24713.
31. Arnesen T, Starheim KK, Van Damme P, Evjenth R, Dinh H, Betts MJ et al. The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntingtin aggregation. Mol Cell Biol 2010; 30: 1898-1909.
32. Arnesen T, Anderson D, Torsvik J, Halseth HB, Varhaug JE, Lillehaug JR. Cloning and characterization of hNAT5/hSAN: an evolutionarily conserved component of the NatA protein N-alpha-acetyltransferase complex. Gene 2006; 371: 291-295.
33. Van Damme P, Evjenth R, Foyn H, Demeyer K, De Bock PJ, Lillehaug JR et al. Proteome-derived peptide libraries allow detailed analysis of the substrate specificities of N{alpha}-acetyltransferases and Point to hNaa10p as the post-translational actin N{alpha}-acetyltransferase. Mol Cell Proteomics 2011; 10: M110 004580.
34. Mullen JR, Kayne PS, Moerschell RP, Tsunasawa S, Gribskov M, Colavito-Shepanski M et al. Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. EMBO J 1989; 8: 2067-2075.
35. Starheim KK, Gromyko D, Velde R, Varhaug JE, Arnesen T. Composition and biological significance of the human Nalpha-terminal acetyltransferases. BMC Proc 2009; 3 (Suppl 6): S3.
36. Song OK, Wang X, Waterborg JH, Sternglanz R. An Nalpha-acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 and H2A. J Biol Chem 2003; 278: 38109-38112.
37. Marmorstein R. Biochemical and structural characterization of recombinant histone acetyltransferase proteins. Methods Enzymol 2004; 376: 106-119.
38. Rope AF, Wang K, Evjenth R, Xing J, Johnston JJ, Swensen JJ et al. Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. Am J Hum Genet 2011; 89: 28-43.
39. Lee CF, Ou DS, Lee SB, Chang LH, Lin RK, Li YS et al. hNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing. J Clin Invest 2010; 120: 2920-2930.
40. Ren T, Jiang B, Jin G, Li J, Dong B, Zhang J et al. Generation of novel monoclonal antibodies and their application for detecting ARD1 expression in colorectal cancer. Cancer Lett 2008; 264: 83-92.
41. Midorikawa Y, Tsutsumi S, Taniguchi H, Ishii M, Kobune Y, Kodama T et al. Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J Cancer Res 2002; 93: 636-643.
42. Yu M, Gong J, Ma M, Yang H, Lai J, Wu H et al. Immunohistochemical analysis of human arrest-defective-1 expressed in cancers in vivo. Oncol Rep 2009; 21: 909-915.
43. Yu M, Ma M, Huang C, Yang H, Lai J, Yan S et al. Correlation of expression of human arrest-defective-1 (hARD1) protein with breast cancer. Cancer Invest 2009; 27: 978-983.
44. Fisher TS, Etages SD, Hayes L, Crimin K, Li B. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J Biol Chem 2005; 280: 17749-17757.
45. Funderburk SF, Wang QJ, Yue Z. The Beclin 1-VPS34 complex-at the crossroads of autophagy and beyond. Trends Cell Biol 2010; 20: 355-362.
46. Arnesen T, Gromyko D, Pendino F, Ryningen A, Varhaug JE, Lillehaug JR. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene 2006; 25: 4350-4360.
47. Gromyko D, Arnesen T, Ryningen A, Varhaug JE, Lillehaug JR. Depletion of the human N(alpha)-terminal acetyltransferase A (hNatA) induces p53-dependent apoptosis and p53-independent growth inhibition. Int J Cancer 2010; 127: 2777-2789.
48. Lim JH, Park JW, Chun YS. Human arrest defective 1 acetylates and activates betacatenin, promoting lung cancer cell proliferation. Cancer Res 2006; 66: 10677-10682.
49. Seo JH, Cha JH, Park JH, Jeong CH, Park ZY, Lee HS et al. Arrest defective 1 autoacetylation is a critical step in its ability to stimulate cancer cell proliferation. Cancer Res 2010; 70: 4422-4432.
50. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007; 6: 24.
51. Motokura T, Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev 1993; 3: 5-10.
52. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
53. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet 2000; 1: 11-19.
54. Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal 2010; 3: ra9.
55. Hua KT, Tan CT, Johansson G, Lee JM, Yang PW, Lu HY et al. N-alphaacetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity. Cancer Cell 2011; 19: 218-231.
56. Shin DH, Chun YS, Lee KH, Shin HW, Park JW. Arrest defective-1 controls tumor cell behavior by acetylating myosin light chain kinase. PLoS One 2009; 4: e7451.
57. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290: 1717-1721.
58. Yi CH, Sogah DK, Boyce M, Degterev A, Christofferson DE, Yuan J. A genome-wide RNAi screen reveals multiple regulators of caspase activation. J Cell Biol 2007; 179: 619-626.
59. Yi CH, Pan H, Seebacher J, Jang IH, Hyberts SG, Heffron GJ et al. Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell 2011; 146: 607-620.
60. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
61. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
62. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9(Suppl 5): 10-17.
63. Bacon AL, Harris AL. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med 2004; 36: 530-539.
64. Hopfl G, Ogunshola O, Gassmann M. HIFs and tumors-causes and consequences. Am J Physiol Regul Integr Comp Physiol 2004; 286: R608-R623.
65. Zhou J, Schmid T, Schnitzer S, Brune B. Tumor hypoxia and cancer progression. Cancer Lett 2006; 237: 10-21.
66. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 2004; 19: 176-182.
67. Poellinger L, Johnson RS. HIF-1 and hypoxic response: the plot thickens. Curr Opin Genet Dev 2004; 14: 81-85.
68. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002; 16: 1151-1162.
69. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343-354.
70. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
71. Lim JH, Chun YS, Park JW. Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin. Cancer Res 2008; 68: 5177-5184.
72. Arnesen T, Kong X, Evjenth R, Gromyko D, Varhaug JE, Lin Z et al. Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha. FEBS Lett 2005; 579: 6428-6432.
73. Murray-Rust TA, Oldham NJ, Hewitson KS, Schofield CJ. Purified recombinant hARD1 does not catalyse acetylation of Lys532 of HIF-1alpha fragments in vitro. FEBS Lett 2006; 580: 1911-1918.
74. Bilton R, Mazure N, Trottier E, Hattab M, Dery MA, Richard DE et al. Arrestdefective-1 protein, an acetyltransferase, does not alter stability of hypoxiainducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem 2005; 280: 31132-31140.
75. Arnesen T, Gromyko D, Horvli O, Fluge O, Lillehaug J, Varhaug JE. Expression of N-acetyl transferase human and human Arrest defective 1 proteins in thyroid neoplasms. Thyroid 2005; 15: 1131-1136.
76. Fluge O, Bruland O, Akslen LA, Varhaug JE, Lillehaug JR. NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene 2002; 21: 5056-5068.
77. Martin DT, Gendron RL, Jarzembowski JA, Perry A, Collins MH, Pushpanathan C et al. Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors. Clin Cancer Res 2007; 13: 1480-1487.
78. Gendron RL, Adams LC, Paradis H. Tubedown-1, a novel acetyltransferase associated with blood vessel development. Dev Dyn 2000; 218: 300-315.
79. Arnesen T, Betts MJ, Pendino F, Liberles DA, Anderson D, Caro J et al. Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase. BMC Biochem 2006; 7: 13.
80. Sugiura N, Adams SM, Corriveau RA. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J Biol Chem 2003; 278: 40113-40120.
81. Line A, Stengrevics A, Slucka Z, Li G, Jankevics E, Rees RC. Serological identification and expression analysis of gastric cancer-associated genes. Brit J Cancer 2002; 86: 1824-1830.
82. Huang GL, Li BK, Zhang MY, Zhang HZ, Wei RR, Yuan YF et al. LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 2046-2054.
83. Ametzazurra A, Larrea E, Civeira MP, Prieto J, Aldabe R. Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis. Oncogene 2008; 27: 7296-7306.
84. Liu Z, Liu Y, Wang H, Ge X, Jin Q, Ding G et al. Patt1, a novel protein acetyltransferase that is highly expressed in liver and downregulated in hepatocellular carcinoma, enhances apoptosis of hepatoma cells. Int J Biochem Cell Biol 2009; 41: 2528-2537.
85. Hou F, Chu CW, Kong X, Yokomori K, Zou H. The acetyltransferase activity of San stabilizes the mitotic cohesin at the centromeres in a shugoshin-independent manner. J Cell Biol 2007; 177: 587-597.
86. Williams BC, Garrett-Engele CM, Li Z, Williams EV, Rosenman ED, Goldberg ML. Two putative acetyltransferases, san and deco, are required for establishing sister chromatid cohesion in Drosophila. Curr Biol 2003; 13: 2025-2036.
87. Pimenta-Marques A, Tostoes R, Marty T, Barbosa V, Lehmann R, Martinho RG. Differential requirements of a mitotic acetyltransferase in somatic and germ line cells. Dev Biol 2008; 323: 197-206.
88. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer 2001; 1: 109-117.